Kardigan, Inc.
KARD
NASDAQ23.82
USD
-0.53
- -
ISIN
US4859251013
CUSIP
485925101
Return %
Stock
S&P500
1Y
8.26
20.98
3Y
8.26
70.79
5Y
8.26
73.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Tassos Gianakakos
- Full Time Employees
- 231
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 506 Carnegie Center Drive Princeton NJ United States of America 08540
- IPO Date
- Jun 18, 2026
- Website
- kardigan.bio
- Similar Companies
- Business
- Kardigan, Inc. is a late-stage biotechnology company focused on precision cardiovascular therapies and data-enabled clinical development. The company develops targeted medicines intended to modify underlying cardiovascular disease biology and move patients beyond symptom management toward functional cures, while leveraging wearable-sensor data and AI-driven analytics through its proprietary Prolaio platform to support trials and digital endpoints. Kardigan operates primarily in the United States, with headquarters in South San Francisco, California, and is organized around three lead programs designed to address genetic and structural heart diseases as well as hypertension management. The firm’s core mission centers on delivering multiple therapies in parallel to address root causes of cardiovascular disease, aiming to redefine treatment paradigms and improve long-term patient outcomes. Kardigan maintains a portfolio approach that combines drug development with an integrated analytics layer to accelerate discovery, optimize trial design, and facilitate data-driven decision-making across its development programs. Founding year is 2023, and the company positions itself as a modern, patient-driven organization seeking to transform cardiovascular care through disease-modifying medicines and digital trial innovations. Major recent actions include advancing lead programs through late-stage development, securing strategic funding rounds to support portfolio progression, and expanding its data and analytics capabilities via Prolaio to enhance clinical trial endpoints and trial efficiency.
First Look: Tech Selloff, SCOTUS Weed Killer Ruling, USPS Update
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan rises in Nasdaq debut after upsized $400 million IPO
Kardigan Announces Pricing of Upsized Initial Public Offering
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
Kardigan Begins Process For IPO On Cardiovascular Treatments Promise